# Phase 2 Glomerulonephritis, IGA trials recruiting: 28 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 2 for Glomerulonephritis, IGA that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Glomerulonephritis, IGA trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/glomerulonephritis-iga

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07889362 | A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN) | Biogen | Phase 2 | Not yet recruiting | Immunoglobulin A Nephropathy | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889362) |
| August 25, 2026 | NCT07785128 | Efficacy and Safety of Mycophenolate Mofetil in Refractory IgA Nephropathy | Shaheed Suhrawardy Medical College and Hospital | Phase 2 | Not yet recruiting | IgA Nephropathy | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07785128) |
| August 19, 2026 | NCT07773727 | A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN | argenx | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773727) |
| July 28, 2026 | NCT07730632 | Phase II Clinical Study on the Efficacy and Safety of QLS7305 in Patients With Kidney Disease (Part A) | Qilu Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | IgAN - IgA Nephropathy, Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy (C3G)... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730632) |
| June 1, 2026 | NCT07616700 | A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy | Haisco Pharmaceutical Group Co., Ltd. | Phase 2 | Recruiting | IgA Nephropathy (IgAN) | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07616700) |
| May 29, 2026 | NCT07614477 | Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular... | Everest Medicines (China) Co.,Ltd. | Phase 2 | Recruiting | Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614477) |
| May 12, 2026 | NCT07582133 | A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy | Chengdu Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Primary IgA Nephropathy | 380 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582133) |
| April 28, 2026 | NCT07553494 | SLN12140 in Adult Participants With IgA Nephropathy in China | Linno Pharmaceuticals, Inc. | Phase 2 | Not yet recruiting | IgA Nephropathy (IgAN) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553494) |
| April 21, 2026 | NCT07541287 | A Study of JADE101 in Participants With Immunoglobulin A Nephropathy | Jade Biosciences, Inc. | Phase 2 | Recruiting | IgA Nephropathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07541287) |
| April 13, 2026 | NCT07522099 | Chinese Adults With Kidney Disease | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522099) |
| March 16, 2026 | NCT07474636 | Efficacy and Safety Study of HS-10542 for IgA Nephropathy | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 | Not yet recruiting | IgAN, Immunoglobulin A Nephropathy (IgAN), Glomerular Disease | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07474636) |
| January 21, 2026 | NCT07354932 | A Study of SHR-2173 in Participants With Primary IgA Nephropathy | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 2 | Recruiting | Primary IgA Nephropathy | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354932) |
| August 28, 2025 | NCT07146906 | A Study to Assess the Effects of Zigakibart on IgA Nephropathy. | Novartis Pharmaceuticals | Phase 2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07146906) |
| May 25, 2025 | NCT06989359 | Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease | ADARx Pharmaceuticals, Inc. | Phase 2 | Recruiting | IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06989359) |
| May 21, 2025 | NCT06983028 | Atacicept in Multiple Glomerular Diseases | Vera Therapeutics, Inc. | Phase 2 | Recruiting | pMN, IgAN, Nephrotic Syndrome, MCD, FSGS | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06983028) |
| May 21, 2025 | NCT06982040 | Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | Nanjing Chia-tai Tianqing Pharmaceutical | Phase 2 | Not yet recruiting | Primary IgA Nephropathy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06982040) |
| February 17, 2025 | NCT06830395 | Study of CM313 in Subject With IgA Nephropathy | Keymed Biosciences Co.Ltd | Phase 2 | Not yet recruiting | IgA Nephropathy | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06830395) |
| January 28, 2025 | NCT06797518 | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | Novartis Pharmaceuticals | Phase 2 | Recruiting | Glomerulonephritis, IGA, Immunoglobulin A Nephropathy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06797518) |
| November 13, 2024 | NCT06687174 | Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) | Wuhan Createrna Science and Technology Co., Ltd | Phase 2 | Not yet recruiting | IgA Nephropathy (IgAN) | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06687174) |
| November 6, 2024 | NCT06676579 | Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) | Mayo Clinic | Phase 2 | Recruiting | IgA Nephropathy (IgAN) | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06676579) |
| June 20, 2024 | NCT06466135 | Study of WAL0921 in Patients With Glomerular Kidney Diseases | Walden Biosciences | Phase 2 | Recruiting | Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06466135) |
| June 12, 2024 | NCT06454110 | Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) | NovelMed Therapeutics | Phase 2 | Not yet recruiting | IgA Nephropathy | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06454110) |
| May 17, 2024 | NCT06419205 | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G | Akebia Therapeutics | Phase 2 | Recruiting | IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06419205) |
| April 5, 2024 | NCT06350630 | Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study | Centre Hospitalier Universitaire de Saint Etienne | Phase 2 | Recruiting | IgA Nephropathy | 334 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06350630) |
| March 20, 2023 | NCT05775042 | Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy | Keymed Biosciences Co.Ltd | Phase 2 | Recruiting | IgA Nephropathy | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05775042) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| [Keymed Biosciences Co.Ltd](https://specstream.ai/data/clinical-trials/company/keymed-biosciences-co-ltd) | 2 |
| ADARx Pharmaceuticals, Inc. | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Walden Biosciences | 1 |
| [Jiangsu Hansoh Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/jiangsu-hansoh-pharmaceutical-co-ltd) | 1 |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 1 |
| NovelMed Therapeutics | 1 |
| [argenx](https://specstream.ai/data/clinical-trials/company/argenx) | 1 |
| Kira Pharmacenticals (US), LLC. | 1 |
| Travere Therapeutics, Inc. | 1 |
| Centre Hospitalier Universitaire de Saint Etienne | 1 |
| Linno Pharmaceuticals, Inc. | 1 |
| [Akebia Therapeutics](https://specstream.ai/data/clinical-trials/company/akebia-therapeutics) | 1 |
| Nanjing Chia-tai Tianqing Pharmaceutical | 1 |
| University of Leicester | 1 |
| Mayo Clinic | 1 |
| Vera Therapeutics, Inc. | 1 |
| [Guangdong Hengrui Pharmaceutical Co., Ltd](https://specstream.ai/data/clinical-trials/company/guangdong-hengrui-pharmaceutical-co-ltd) | 1 |
| Shaheed Suhrawardy Medical College and Hospital | 1 |
| Wuhan Createrna Science and Technology Co., Ltd | 1 |
| Jade Biosciences, Inc. | 1 |
| Everest Medicines (China) Co.,Ltd. | 1 |
| [Biogen](https://specstream.ai/data/clinical-trials/company/biogen) | 1 |
| [Chengdu Suncadia Medicine Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chengdu-suncadia-medicine-co-ltd) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 13 |
| United States | 10 |
| South Korea | 4 |
| United Kingdom | 4 |
| Australia | 3 |
| Italy | 3 |
| Spain | 3 |
| Taiwan | 3 |
| Malaysia | 2 |
| Brazil | 2 |
| Germany | 2 |
| Japan | 2 |
| Poland | 2 |
| India | 1 |
| Sri Lanka | 1 |
| Czechia | 1 |
| Netherlands | 1 |
| Sweden | 1 |
| France | 1 |
| Hong Kong | 1 |
| Bangladesh | 1 |
| New Zealand | 1 |
| Argentina | 1 |
| Israel | 1 |
| Saudi Arabia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Nigerian restaurants in the United States](https://specstream.ai/data/businesses/nigerian-restaurants/united-states)
- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Dental clinics in the United States](https://specstream.ai/data/businesses/dental-clinics/united-states)
- [Masonry and concrete contractors in the United States](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Cleaning products suppliers in the United States](https://specstream.ai/data/businesses/cleaning-products-suppliers/united-states)
